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Despite a flood of research on the topic, 
rates of allergy and allergy-induced 
asthma continue to climb in most indus-
trialized nations. Holt, a professor at the 
Telethon Institute for Child Health 
Research in Perth, Australia, wants to 
reverse that trend. To accomplish this, 
he needs to know what triggers airborne 
allergy and asthma, starting at the mo-
ment babies draw their first breath. He’s 
currently co-leading the first clinical trial 
to test a treatment that could prevent 
asthma in children who are genetically 
predisposed to the disease. The idea 
behind the treatment, consisting of daily 
drops of dust mite, cat, and grass antigen 
placed under the tongue, builds on his 
earlier studies showing that inhaled 
antigens can induce immunological 
tolerance (1), a process that involves 
regulatory T cells (2).
Dendritic cells (DCs) in airways 
feature prominently in Holt’s research. 
These potent antigen-
presenting cells help deter-
mine whether responses to 
inhaled allergens will be 
dominated by Th1 or Th2 
cells (3). But even before 
DCs get involved, a bevy 
of factors—genetics, pre- 
and postnatal antigen ex-
posure, and nitric oxide 
levels, to name just a few—
determine whether expo-
sure will lead to tolerance 
or hyperreactivity. Holt has 
studied these factors and 
believes many of them can be overcome. 
The main obstacle in taming asthma, he 
says, is an outdated mind-set.
Is it true that Australia has one of the 
highest rates of asthma in the world?
It’s true. Australia and New Zealand 
were on top for a long time, but now 
we’ve been joined by lots of European 
countries and the US, so we aren’t as far 
in front as we used to be.
Why has Australia remained high?
Everyone has pet theories, but I think 
we’re just an archetypal example of 
what has happened in the western 
world since World War II. Since the 
’60s, there has been a slow surge in the 
prevalence of allergic disease and aller-
gic asthma in westernized countries. 
We see the same rise now happening in 
second world countries as they move 
into fi  rst world economies.
Are there any confounding factors in 
this trend?
There isn’t anything major; this is a real 
thing. We’re talking about 35 years of 
research. When we look at pediatric 
records starting in the ’70s, we can see 
changes occurring in succeeding birth 
cohorts so that each new generation of 
children has a progressively higher risk 
for allergic sensitization and subsequent 
asthma. We’re also seeing this trend in 
autoimmune disease.
Do you think diff  erences in the way kids 
are raised now might account for this trend?
Sure. There are obvious diff  erences like 
processed foods. But also, everything 
sparkles these days. You go into the super-
market and there are hundreds of cleaning 
products to spray on every surface to 
keep microbes away. That was unheard 
of when I was a kid. Clean houses used 
to be houses that were vacuumed and 
swept once a week.
There was a study done by a group 
in the UK that found that kids who 
basically lived in a bubble—whose fam-
ilies avoided every allergen they could—
had higher levels of allergic sensitization 
by the time they were of school age.
Have changes in vitamin intake and 
nutrition infl  uenced asthma prevalence?
I think so. Everything about allergy and 
asthma is multi-factorial. There’s evi-
dence that vitamin D defi  ciencies limit 
the rate at which the immune system 
matures. And the story here is that kids 
don’t go outside as much as they used to, 
which could lead to vitamin D defi  cien-
cies. Epidemiologists have been mapping 
risk for asthma and allergy in relation to 
population levels of vitamin D, and they 
are seeing a connection.
There’s also the omega-3 story. These 
fatty acids from fish have immunomod-
ulatory effects that we don’t completely 
understand, but if you look in populations 
that eat oily fish, the levels of asthma and 
allergic disease tend to be lower. A range 
of other dietary factors appear to contrib-
ute, but quantifying their effects is difficult 
because they vary in relation to how 
stressed an individual population is with 
respect to a particular set of components. 
For example, if a population lives in an 
environment where it’s difficult to get 
green vegetables, vitamin deficiency may 
show up as a risk factor for allergy and 
asthma; whereas if the population is well 
nourished, it might not.
Do you think there’s a way to reverse the 
rising trend without reverting back to less 
sanitary days?
This is basically what’s at the heart of 
what we’re doing now in our human 
studies. We think there are incredible 
opportunities for changing population 
patterns of lifelong asthma by attacking 
problems in early pediatrics instead of 
waiting until kids have permanent asthma. 
We know that the major changes respon-
sible for the burden of disease in adult life 
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occur in the fi  rst seven years of life. Plus, 
many of the tools we have could be 
revised only slightly to prevent the onset 
of disease. The real challenge is to convince 
the pharmaceutical industry and regula-
tory authorities like the FDA that young 
children should be the principle targets in 
controlling these diseases (4).
Do you worry that the “bottom line” could 
get in the way of changing their approach 
to treatment?
No, because from a business modeling 
perspective this works too. If it is possi-
ble to safely treat early stage disease, the 
size of the market is large and the poten-
tial health benefi  ts are extremely high. If 
industry management actually sits down 
and does the math, they’ll fi  nd that there 
is plenty of potential to make the same 
amount of money by switching the 
emphasis to diff   erent age groups for 
treatment. The obstacle is getting people 
to change their mind-set. Since time 
immemorial, the pharmaceutical indus-
try has specialized in treating chronic 
diseases—with the exception of infec-
tious diseases. But now a new generation 
of people in pharma is starting to get the 
message, and these are the people we’re 
trying to build relationships with so that 
we can help them make this transition.
The main thing is that information 
should not stay in the realm of mouse 
immunology, even though that’s where 
it started. That’s why I have stepped 
into the human arena too.
What are you doing there?
We have one NIH-funded trial, for 
example, based on the idea that if you can 
treat children who are at high genetic risk 
of allergic disease in a way that promotes 
the natural development of immuno-
logical tolerance, you’ll take away their risk 
for long-term asthma. The trial was based 
on experimental animal data that we got 
back in the early ’80s, which revealed the 
phenomenon known as inhalation toler-
ance—the equivalent of oral tolerance in 
the gut, which protects us from becoming 
allergic to proteins in the food we eat. 
Our immune system develops as it’s 
exposed to airborne antigens like dust 
mite or cat proteins and makes up its 
mind about whether or not it’s going to 
develop positive immunity or tolerance. 
Most children are non-allergic, and the 
capacity to generate IgE antibody to these 
proteins is permanently switched off   by 
the successful development of tolerance.
We had also discovered that children 
who have the highest risk of asthma come 
from families with a history of allergic 
disease. And, at least in the animal equiv-
alent of these children, they need more 
intense stimulation and longer stimula-
tion by these everyday antigens in the 
environment [to become tolerant]. This 
led to our prediction that they would 
benefit from high levels of stimulation.
At this point, we’ve put 50 children 
through the trial, including children as 
young as 12 months of age. We gave the 
children a mixture of four major inhal-
ant allergens in the form of drops under 
their tongues on a daily basis for a year.
Have there been adverse eff  ects?
No, the children have had no symptoms 
of sensitization and there have been no 
increased levels of IgE. Therefore, the 
theoretical danger that we might do the 
opposite that we set out to do—sensitize 
instead of tolerize—does not seem to be 
a problem. However, we need to wait for 
a few years before we assess the effi   cacy 
of the treatment.
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Are there immune factors that are critical 
in determining tolerance or immunity?
Absolutely. There are probably about 10 
cytokines that you would say are more 
important than the other 50 or so. These 
are things like IL-4, IL-5, IL-9, IL-13, 
interferon-, and TNF. What we really 
want to know is what are the master 
switches. We’ve found some gatekeepers, 
such as dendritic cells in the airway 
mucosa. They are the ultimate arbitra-
tors in deciding whether an inhaled 
protein is going to induce tolerance or 
positive immunity. The Toll-like receptor 
system is probably involved too. And 
there are shared processes that determine 
the kinetics of postnatal maturation of 
immune competence in the preschool 
years. It looks like the faster your im-
mune system matures, the lower your 
risk is of programming long-term aller-
gic responses. To the extent that the 
hygiene hypothesis is concerned, micro-
bial stimulation is probably the most 
important signal driving that maturation.
Do you have children?
I sure do. And grandchildren.
What is your fatherly advice with respect 
to avoiding allergies and asthma?
My kids are advised to breast-
feed their children for the 
fi   rst six months of life be-
cause it’s the best protection 
that we have now against 
early severe infection, which 
we know synergizes with 
allergy to create maximum 
risk for developing long-
term asthma (5). And al-
though I wouldn’t go out 
and trumpet this, I’m person-
ally convinced about the epi-
demiology data saying that 
early pet exposure is good 
for you. I also recommend a 
healthy diet and contact with 
the outside environment. We 
always allowed our kids to crawl around 
in the garden so that their immune system 
could say hello to the world out there.
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DCs in the airway mucosa (above) can respond 
to inhaled antigens in a way that triggers an 
asthma attack.
There are 
incredible 
opportunities 
for changing 
population 
patterns of 
lifelong 
asthma by 
attacking 
problems 
in early 
pediatrics.